Septerna Cash Flow Statement
NASDAQ: SEPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
38.37+1.47 (+3.98%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Septerna free cash flow
In fiscal 2025, Septerna generated $110.2 million of operating cash flow and spent $518,000 on capital expenditures. That left free cash flow of $109.7 million, a free-cash-flow margin of 238.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Septerna cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -48.88M | -71.80M | 4.18M |
| Net Income growth (YoY) | — | -1817.66% | — |
| Depreciation & Amortization | 1.60M | 1.40M | 800.00K |
| Stock-Based Compensation | 8.48M | 3.15M | 1.62M |
| Change in Working Capital | 164.05M | 533.00K | -639.00K |
| Operating Cash Flow | 110.19M | -67.47M | -38.72M |
| Capital Expenditures | -518.00K | -2.10M | -2.88M |
| Investing Cash Flow | -229.35M | -160.60M | 22.12M |
| Financing Cash Flow | 1.69M | 377.78M | 74.52M |
| Net Change in Cash | -117.47M | 149.71M | 57.92M |
| Free Cash Flow | 109.67M | -69.57M | -41.60M |
This table shows 3 annual periods of Septerna's cash flow statement, from FY 2025 back to FY 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SEPN's reporting calendar. What is a cash flow statement?